Overview

Safety, Tolerability, and Efficacy of CLTX-305 in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

Status:
Active, not recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

A Phase 2b open label, dose finding study to evaluate the Safety, Tolerability and Efficacy of CLTX-305 (encaleret) in Autosomal Dominant Hypocalcemia (ADH) Type 1

Phase:

Phase 2

Details

Lead Sponsor:

Calcilytix Therapeutics, Inc.
Calcilytix Therapeutics, Inc., a BridgeBio company